|
|
|
@ -25,7 +25,8 @@ Hyrimoz, Idacio, Simlandi, Yuflyma, and Yusimry),
|
|
|
|
the biosimilars are required to prove they have similar efficacy and safety to the
|
|
|
|
the biosimilars are required to prove they have similar efficacy and safety to the
|
|
|
|
reference drug.
|
|
|
|
reference drug.
|
|
|
|
|
|
|
|
|
|
|
|
When registering these clinical trials
|
|
|
|
When registering a clinical trial,
|
|
|
|
|
|
|
|
the investigators are required to
|
|
|
|
% discuss how these are registered and what data is published.
|
|
|
|
% discuss how these are registered and what data is published.
|
|
|
|
% Include image and discuss stages
|
|
|
|
% Include image and discuss stages
|
|
|
|
% Discuss challenges faced
|
|
|
|
% Discuss challenges faced
|
|
|
|
|